Key result
Exposure to renin-angiotensin system blockades did not significantly increase mean serum potassium compared to no exposure in maintenance haemodialysis patients (5.48 vs 5.54 mmol/l, P=NS).
Why the study?
Do ACEIs and/or ARBs increase the risk of hyperkalaemia in patients on maintenance haemodialysis?
Population
69 patients on maintenance haemodialysis
Comparison
Renin-angiotensin system blockades for 1 month… vs No exposure to RAS blockades for 1 month
Design
Cohort
Follow-up
3 months (1 month per period)
Authors
Loading...
May support RAS blockade without excess hyperkalaemia risk in haemodialysis; leaves open randomized confirmation, especially in anuric patients.
Do ACEIs and/or ARBs increase the risk of hyperkalaemia in patients on maintenance haemodialysis?
Absolute Event Rate: 5.48% vs 5.54%
p-value: p=NS
RAS blockade with ACEI, ARB, or both does not significantly increase the risk of hyperkalaemia in maintenance haemodialysis patients, though caution is warranted in anuric patients.
Han et al. (2007) studied maintenance haemodialysis (n=69). Renin-angiotensin system (RAS) blockades (ACEI and/or ARB) vs. No exposure to RAS blockades was evaluated on Mean serum potassium (mmol/l) (p=NS). Exposure to renin-angiotensin system blockades did not significantly increase mean serum potassium compared to no exposure in maintenance haemodialysis patients (5.48 vs 5.54 mmol/l, P=NS).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: